insurance changes for glp-1 drugs Perspectives from employers on the costs and issues associated with covering agonists weight loss Live Updates: Insurance Coverage for

Mitrofanova, A., Merscher, S

This date reflects the maximum time the compounded preparation is expected to remain stable under proper storage conditions

Smaller contributions from cardiovascular and endocrinology specialists may reflect patients with more complex cardiometabolic profiles

Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53

It was fantastic to co-present with Luke Greenwalt to discuss the interplay between the US market, the largest value driver and origin of many of the trends which will have resonance elsewhere in the world, with the global markets where critical trends such as off-patent semaglutide, or long term Real World Outcomes studies, will shape policies and the competitive dynamics of the market for the next decade of development